rs2073658 — USF1 USF1 FCHL Variant

USF1 — The Transcription Factor at the Heart of Familial Hyperlipidemia

When researchers searched for the genetic root of familial combined hyperlipidemia — the most common inherited lipid disorder, affecting 1–2% of the population and responsible for a disproportionate share of premature coronary disease — the trail led to USF1. This gene encodes upstream stimulatory factor 1¹¹ upstream stimulatory factor 1
USF1 is a basic helix-loop-helix leucine zipper transcription factor that binds E-box motifs in the promoters of dozens of metabolic genes, a master regulator of lipid and glucose metabolism that controls expression of ABCA1, APOA5, APOE, fatty acid synthase, and microsomal triglyceride transfer protein (MTP), among others. The rs2073658 variant sits within an intron of USF1 but has measurable effects on how the gene responds to insulin — effects that ripple outward to triglyceride secretion and cardiovascular risk.

The Mechanism

rs2073658 does not change the USF1 protein directly; instead it sits within a FOXA2 binding site²² FOXA2 binding site
FOXA2 (forkhead box protein A2) is a transcription factor that itself regulates USF1 transcription; the two proteins form a feed-forward regulatory loop in the USF1 gene. Functional studies by Auer et al. showed that constructs carrying the major (C) allele display higher transcriptional activity than minor (T) allele constructs. When FOXA2 is knocked down, it reduces activity of major allele constructs but not minor allele constructs — indicating that the C allele sustains a feed-forward loop in which FOXA2 activates USF1 transcription and USF1 in turn activates FOXA2, driving expression of MTP and thereby hepatic triglyceride secretion.

The T risk allele disrupts this loop in a different way under metabolic conditions: the Naukkarinen 2009 study³³ Naukkarinen 2009 study
Naukkarinen et al. Functional variant disrupts insulin induction of USF1: mechanism for USF1-associated dyslipidemias. Circ Cardiovasc Genet, 2009 profiled fat and muscle biopsies before and after a euglycemic hyperinsulinemic clamp in 47 and 118 individuals respectively. The risk allele of rs2073658 eradicated the normal inductive effect of insulin on USF1 expression in both tissues, leading to perturbed expression of downstream target genes in adipose tissue. The net effect: T allele carriers respond abnormally to insulin at the level of gene regulation, producing a dyslipidemias-prone transcriptional state.

The Evidence

The foundational evidence came from a 2004 Nature Genetics study⁴⁴ 2004 Nature Genetics study
Pajukanta et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nature Genetics, 2004 of 60 extended Finnish FCHL families comprising 721 genotyped individuals. Association between USF1 haplotypes and FCHL reached p=0.00002 overall, with a striking p=0.0000009 in males with elevated triglycerides. Carriers of the risk USF1 haplotype showed altered expression of USF1 target genes in fat tissue. This was the first gene definitively associated with FCHL, a disorder previously known only by its phenotype.

Independent replication followed promptly. A study in 314 individuals from 24 Mexican FCHL families⁵⁵ 314 individuals from 24 Mexican FCHL families
Huertas-Vazquez et al. Familial combined hyperlipidemia in Mexicans. Arterioscler Thromb Vasc Biol, 2005 found significant association between rs2073658 and FCHL and triglyceride traits (p=0.0009 for the strongest association), providing independent cross-ethnic evidence. A large Utah pedigree study of 2,195 subjects across 87 families replicated the association with FCHL, LDL cholesterol, and triglycerides (p=0.001–0.05), with the strongest effects in males.

The biological stakes were clarified by a 2016 Science Translational Medicine study⁶⁶ Science Translational Medicine study
Laurila et al. USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. Sci Transl Med, 2016 showing that individuals carrying variants that reduce USF1 expression have improved insulin sensitivity, a favorable lipid profile (higher HDL, lower TG), and reduced atherosclerosis burden — consistent with T allele carriers having reduced but dysregulated USF1 activity under insulin signaling.

Practical Actions

For T allele carriers, the key levers are reducing hepatic triglyceride production triggers and supporting the insulin-responsive gene regulation pathway that rs2073658 impairs. Limiting dietary saturated and trans fat reduces MTP substrate and hepatic VLDL assembly. Omega-3 fatty acids (EPA/DHA) independently reduce hepatic triglyceride synthesis and VLDL secretion via PPAR-alpha activation, providing a complementary pathway bypass. Monitoring fasting triglycerides, LDL particle number, and apoB is more informative than total cholesterol alone for this variant, since FCHL involves elevated apoB-rich particles across multiple lipoprotein fractions.

TT homozygotes carry two copies of the risk haplotype and have the highest liability for developing the full FCHL phenotype; a lipid specialist assessment is appropriate if triglycerides or LDL remain elevated after dietary optimization.

Interactions

USF1 regulates APOA5, APOE, and ABCA1 — genes with their own common variants in the GeneOps database. The APOA5 rs662799 variant (APOA5*3 haplotype) reduces APOA5 expression and elevates triglycerides; combined carriage of USF1 T and APOA5*3 likely compounds triglyceride burden through distinct but additive mechanisms. The related USF1 SNP rs3737787 (in the 3' UTR) tags the same risk haplotype and was the primary variant studied in several of the replication cohorts; both rs2073658 and rs3737787 track the same USF1 risk haplotype and are in high linkage disequilibrium in European populations.